Triad Securities is pleased to announce the formation of Triad Healthcare Partners, a division of Triad Securities Corp. The new division will provide investment banking services to pharmaceutical and medical device companies on a global basis. The team will have a particular focus on the specialty pharmaceutical sector. The team will be headed by Andrew Hirschberg. Andrew has been advising specialty pharmaceutical clients for 30 years and has completed over 100 transactions in multiple specialties (dermatology, gastroenterology, pediatrics, nephrology, etc.) with an aggregate value exceeding $5 billion. Also joining him will be Mark Palmer. Mark has led business development for two specialty pharmaceutical companies (Braintree Laboratories, Inc. and Medicis Pharmaceutical Corp.) for the ten years prior to joining Triad Healthcare Partners. During that time, Mark led and completed transactions with an aggregate value of well over $1 billion. These transactions were primarily in dermatology, gastroenterology, orphan drugs and pediatrics.
About Triad Securities
Customers subscribe to Triad's leading IPO report service, execute through its full service agency execution desk or electronic execution system, and have access to front-end prime brokerage technology. Additionally, institutions can now seek out investment banking advice from Triad Healthcare Advisors. Triad also arranges office space for trading groups and hedge funds. For more information about Triad Securities Corp., please visit www.triadsecurities.com; member FINRA, SIPC.